Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 28;10(9):2105.
doi: 10.3390/biomedicines10092105.

A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Hua-Ching Chang  1   2 , Tsung-Jen Wang  3   4 , Ming-Hsiu Lin  1 , Ting-Jui Chen  5
Affiliations
Review

A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Hua-Ching Chang et al. Biomedicines. .

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon but life-threatening diseases mostly caused by drugs. Although various systemic immunomodulating agents have been used, their therapeutic efficacy has been inconsistent. This study aimed to provide an evidence-based review of systemic immunomodulating treatments for SJS/TEN. We reviewed 13 systematic review and meta-analysis articles published in the last 10 years. The use of systemic corticosteroids and IVIg is still controversial. An increasing number of studies have suggested the effectiveness of cyclosporine and biologic anti-TNF-α in recent years. There were also some promising results of combination treatments. Further large-scale randomized controlled trials are required to provide more definitive evidence of the effectiveness of these treatments. The pathogenesis of SJS/TEN has been elucidated in recent years and advances in the understanding of SJS/TEN may inspire the discovery of potential therapeutic targets.

Keywords: Stevens–Johnson syndrome; meta-analysis; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Algorithm for choosing systemic treatments for SJS/TEN.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dodiuk-Gad R.P., Chung W.-H., Valeyrie-Allanore L., Shear N.H. Stevens-Johnson syndrome and toxic epidermal necrolysis: An update. Am. J. Clin. Dermatol. 2015;16:475–493. doi: 10.1007/s40257-015-0158-0. - DOI - PubMed
    1. Yang M.S., Lee J.Y., Kim J., Kim G.W., Kim B.K., Kim J.Y., Park H.W., Cho S.H., Min K.U., Kang H.R. Incidence of Stevens-Johnson Syndrome and Toxic Epi-dermal Necrolysis: A nationwide population-based study using National Health In-surance Database in Korea. PLoS ONE. 2016;11:e0165933. doi: 10.1371/journal.pone.0165933. - DOI - PMC - PubMed
    1. Hsu D.Y., Brieva J., Silverberg N.B., Silverberg J.I. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Investig. Dermatol. 2016;136:1387–1397. doi: 10.1016/j.jid.2016.03.023. - DOI - PubMed
    1. Lerch M., Mainetti C., Beretta-Piccoli B.T., Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin. Rev. Allergy Immunol. 2018;54:147–176. doi: 10.1007/s12016-017-8654-z. - DOI - PubMed
    1. Hoffman M., Chansky P.B., Bashyam A.R., Boettler M.A., Challa N., Dominguez A., Estupinan B., Gupta R., Hennessy K., Huckell S.N., et al. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatol. 2021;157:712–715. doi: 10.1001/jamadermatol.2021.1136. - DOI - PMC - PubMed

LinkOut - more resources